Bailey M Doyinsola, Farge Gaëlle, Mohanty Salini, Breau-Brunel Manon, Roy Gem, de Pouvourville Gérard, de Wazieres Benoit, Janssen Cécile, Tauty Solenne, Bugnard Françoise, Goguillot Mélanie, Bénard Stève, Johnson Kelly D
Value & Implementation Outcomes Research, Merck & Co., Inc., Rahway, NJ, USA.
Health Economics & Outcomes Research, MSD, Puteaux, France.
Hum Vaccin Immunother. 2025 Dec;21(1):2515760. doi: 10.1080/21645515.2025.2515760. Epub 2025 Jul 9.
Pneumococcal disease (PD) is associated with high morbidity and mortality, specifically among individuals ≥65 years of age and those with underlying medical conditions (UMCs). This retrospective cohort study estimated the clinical burden of PD in adults ≥18 years of age with or without UMCs in France. Data were obtained from the French National Health Data System for four yearly cohorts (1 January 2015-31 December 2018). Characteristics of patients with UMCs, with or without PD (UMC population), and the incidence rate and lethality rate of PD leading to hospitalization (in-patient PD population), stratified by age and risk status, were described. In the UMC population ( = 7,947,622; mean age: 65 years), the incidence rate of in-patient PD episodes was 121.98 per 100,000 person-years and was highest among individuals ≥65 years of age (138.52) and in those considered medium-risk (102.45) or high-risk (165.77). In the in-patient PD population ( = 41,885), 59.6% were ≥65 years of age; 1-year all-cause mortality following the initial in-patient PD episode was 26.5%. Individuals ≥65 years of age (regardless of risk status) had a higher risk of PD leading to hospitalization than individuals 18-64 years of age. This study shows a high burden of PD in France due to in-patient PD among adults with UMCs, particularly in those ≥65 years of age, despite their eligibility for pneumococcal vaccination. This highlights the need for higher vaccination coverage, supported by the recent extension of vaccination to all people ≥65 years of age, regardless of their health risk status.
肺炎球菌疾病(PD)与高发病率和高死亡率相关,特别是在65岁及以上的个体以及有基础疾病(UMC)的人群中。这项回顾性队列研究估计了法国18岁及以上有或无基础疾病的成年人中肺炎球菌疾病的临床负担。数据来自法国国家卫生数据系统的四个年度队列(2015年1月1日至2018年12月31日)。描述了有或无肺炎球菌疾病的基础疾病患者(基础疾病人群)的特征,以及按年龄和风险状态分层的导致住院的肺炎球菌疾病的发病率和致死率(住院肺炎球菌疾病人群)。在基础疾病人群(n = 7,947,622;平均年龄:65岁)中,住院肺炎球菌疾病发作的发病率为每10万人年121.98例,在65岁及以上的个体中最高(138.52),在中度风险(102.45)或高风险(165.77)的个体中也最高。在住院肺炎球菌疾病人群(n = 41,885)中,59.6%为65岁及以上;首次住院肺炎球菌疾病发作后的1年全因死亡率为26.5%。65岁及以上的个体(无论风险状态如何)比18 - 64岁的个体因肺炎球菌疾病导致住院的风险更高。这项研究表明,在法国,有基础疾病的成年人中因住院肺炎球菌疾病导致的肺炎球菌疾病负担很高,特别是在65岁及以上的人群中,尽管他们有资格接种肺炎球菌疫苗。这凸显了提高疫苗接种覆盖率的必要性,最近将疫苗接种扩展到所有65岁及以上的人群,无论其健康风险状态如何,为这一需求提供了支持。